PALVELLA THERAPEUTICS, INC. (PVLA) Stock
4 of the hedge funds AlphaScala tracks reported PVLA in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $8.14M. Company insiders reported 0 open-market buys and 35 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own PVLA?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 53K | $8.14M | +196% |
| Millennium Management Israel Englander | 52K | $7.98M | -44% |
| Citadel Ken Griffin | 4K | $537.9K | -83% |
| Marshall Wace | 3K | $435.8K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are PALVELLA THERAPEUTICS, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 14, 26 | Jenkins George M | Director | SELL | 597 | $75K |
| Oct 14, 26 | Jenkins George M | Director | SELL | 476 | $58K |
| Oct 14, 26 | Jenkins George M | Director | SELL | 2.1K | $254K |
| Oct 14, 26 | Jenkins George M | Director | SELL | 2.6K | $321K |
| Oct 14, 26 | Jenkins George M | Director | SELL | 920 | $114K |
| Oct 14, 26 | Jenkins George M | Director | SELL | 505 | $64K |
| Oct 13, 26 | Jenkins George M | Director | SELL | 2.0K | $258K |
| Oct 13, 26 | Jenkins George M | Director | SELL | 1.6K | $212K |
| Oct 13, 26 | Jenkins George M | Director | SELL | 990 | $129K |
| Oct 13, 26 | Jenkins George M | Director | SELL | 1.0K | $136K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →PVLA price chart
Powered by TradingViewWhat does PALVELLA THERAPEUTICS, INC. do?
Pavella Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for rare genetic disorders. The primary function of the company is to research and advance treatments that address unmet medical needs in the realm of genetic diseases, leveraging advanced biotechnological innovations. The company plays a significant role in the health care and pharmaceutical sectors, differentiating itself with its commitment to precision medicine approaches and personalized therapies. By concentrating on niche areas that are often overlooked by larger pharmaceutical firms, Pavella Therapeutics Inc. aims to provide hope and potential treatment options to patients with limited alternatives. In the financial markets, Pavella Therapeutics holds a distinctive position as a cutting-edge firm with the potential to drive significant impacts within its specialized domain. The company's activities contribute to the broader biotechnology landscape by enhancing understanding of genetic conditions and supporting the development of targeted biotherapeutic solutions.